Exclusive distribution in Japan of CSI’s device for treating calcified lesions
First written in FY2017-Q2. 2 of 6 entries say "Cited as achieved", first in FY2021. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023DroppedAnnual report
「The exclusive domestic sales agreement for devices for treating calcified lesions between the Company and U.S.-based Cardiovascular Systems, Inc. ended on 31 January 2023.」
The exclusive domestic sales agreement for CSI’s devices for treating calcified lesions ended on 31 January 2023. - FY2022Cited as achievedAnnual report
「Sales of therapeutic products performed well, led by the “Diamondback360 Coronary Orbital Atherectomy System,” a device for treating calcified lesions in coronary arteries that we began importing and selling in 2018.」
The disclosure again cites the start of imports and sales of CSI’s device in 2018 and strong sales of therapeutic products as achievements. - FY2021Cited as achievedAnnual report
「Sales of therapeutic products performed well, led by the “Diamondback360 Coronary Orbital Atherectomy System,” a device for treating calcified lesions in coronary arteries that we began importing and selling in 2018.」
The disclosure cites the start of imports and sales of CSI’s device in 2018 and strong sales of therapeutic products as achievements. - FY2018AdvancedAnnual report
「Following the listing for reimbursement of the “Diamondback360 Coronary Orbital Atherectomy System MicroCrown,” a device for treating calcified lesions in coronary arteries, effective 1 February 2018, we began training physicians and other healthcare professionals to ensure safe and effective use and worked to expand the number of sales facilities.」
Following the listing for reimbursement of CSI’s device, the Company began training healthcare professionals and moved forward with expanding the number of sales facilities. - FY2017-Q3RestatedAnnual report
「Devices for treating calcified lesions in coronary arteries and lower-limb blood vessels Until the date on which 5 full years have elapsed from the approval date for the reimbursement price of the device for treating calcified lesions in coronary arteries, with renewals every 2 years thereafter」
The disclosure states the products covered by the exclusive domestic sales agreement for CSI’s devices and its term, consisting of 5 years from the approval date for the reimbursement price, followed by renewals every 2 years. - FY2017-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 11 November 2016, the Company resolved to enter into an agreement granting it exclusive sales rights in the Japanese market for devices manufactured by U.S.-based Cardiovascular Systems, Inc. (hereinafter, “CSI”) for the treatment of calcified lesions, and signed the agreement on the same date.」
As a significant subsequent event, the Company acquired exclusive domestic sales rights for devices for treating calcified lesions in coronary arteries and lower-limb blood vessels. It expected to pay US$10 million after signing the agreement and record approximately ¥327 million as selling, general and administrative expenses in the fiscal year ending March 2017.